HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告：#肺癌 非转移性 🔥LungMate-014：新辅助特瑞普利单抗联合化疗联合或不联合Tifcemalimab（抗BTLA抗体）治疗潜在可切除III期非小细胞肺癌：一项随机II期试验 🎙️张鹏博士 🔢2574RO 🎯pCR 32.2% vs 25.4%（n=118）；24个月EFS 71.1% vs 66.0%，24个月OS 83.0% vs 76.1% 🎯非鳞癌和PD-L1 TPS<1%患者获益更大 ☑️NCT05891080 🔗 https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC
热度 2 · 2 赞 · 0 回复 · 0 转发
会议摘要
NCT05891080NCT05891080按 - **标题 / Title：** Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial 对上
- **标题 / Title：** Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial读摘要原文 →来源：HHorinouchi · x.com